SUPAC level 3 changes for MR formulations [Regulatives / Guidelines]

posted by jag009  – NJ, 2019-10-22 23:31 (1498 d 21:50 ago) – Posting: # 20715
Views: 2,346

Hi,

❝ 1. IR product if we change the manufacturing site, do we need to perform BE study as suggested in SUPAC guidance for IR? or it would be okay to justify based on in vitro data?


Did you read the SUPAC guidance for IR?

❝ 2. For MR product SUPAC MR guidance is not clear for any requirement of conducting BE study. where as we do perform Fasting for such changes in manufacturing site change. are we doing correct?


I dont follow. Are you asking if the study should be a fasted study?

J

Complete thread:

UA Flag
Activity
 Admin contact
22,811 posts in 4,783 threads, 1,639 registered users;
18 visitors (0 registered, 18 guests [including 10 identified bots]).
Forum time: 20:21 CET (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5